Chemotherapy, Lung Cancer / 06.04.2014
Non-Small-Cell Lung Cancer: New Agent Effective Against EGFR TKI Resistant Cancer
MedicalResearch.com Interview with:
Dr. Heather Wakalee MD
Associate Professor of Medicine (Oncology)
Stanford University Medical Center
MedicalResearch.com: What are the main findings of the study?
Dr. Wakalee: CO-1686, with the new hydrobromide formulation, has been active at multiple dose levels (500, 750 or 1000 mg orally twice daily). The response rate in patients with EGFR mutant (non-small-cell Lung Cancer) NSCLC that has progressed after therapy with EGFR TKI, and has centrally confirmed T790M, is 64% per RECIST. The majority of responses are ongoing at the time of this report. The drug has been overall very well tolerated.
(more…)